Growth Funding CurifyLabs secured a $14M Series A led by Sandwater and HealthCap with participation from Tesi and Lifeline Ventures, signaling strong investor confidence and funding runway to scale US operations, supply chain, and product innovation.

US Expansion Significant plans to expand US operations, including Jacksonville, Florida, supported by the Series A funding, creating a larger addressable market in North America for automated compounding technology and hospital/pharmacy partnerships.

Aurum Platform Launch of the PharmaPrinter Aurum and platform indicates faster, automated compound capabilities (up to nine times faster than manual workflows), presenting a compelling value proposition for pharmacies and hospitals seeking efficiency gains and patient access.

Strategic Partners Co-led funding with notable investors and participation from Lifeline Ventures and Tesi, along with continued investor involvement, suggests a strong ecosystem for co-development, validation, and potential channel partnerships.

Clinical Adoption Active clinical use of the non-sterile compounding CSS across Europe and the US points to real-world validation, enabling sales conversations with pharmacy groups and hospital networks prioritizing compliant, high-quality automated workflows.